other material
confidence high
sentiment neutral
materiality 0.60
Equillium reports Phase 2 topline data for EQ101 in alopecia areata; 20% of completers achieved SALT ≤20
Equillium, Inc.
- Of 25 completers (baseline SALT 35-100), 20% reached SALT ≤20 at week 24; mean SALT improvement 13.5%.
- In moderate-to-severe subgroup (n=17), 29% achieved SALT ≤20; mean improvement 18.4% from baseline.
- EQ101 well tolerated, no SAEs; 98.9% AEs Grade 1/2; common: URI, headache, fatigue; two Grade 3 events.
- Preliminary PD data show reduction of CD132 on CD8 and NK cells, consistent with target engagement.